The results showed that after immunotherapy, the expression of IGF2BP1/2/3 was significantly downregulated in melanoma and glioblastoma patients, except in the SRP302761 dataset (melanoma) (Figs. 8I–K). This evidence concerns the gene IGF2BP1 and glioblastoma.